{"id":127178,"name":"VERTEX PHARMACEUTICALS","slug":"vertex-pharmaceuticals","state":"MA","description":"Global biotechnology company.","totalSpending":1720000,"filings":24,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":120000},{"year":2020,"income":280000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2024,"income":320000},{"year":2025,"income":280000}],"firms":["TIBER CREEK GROUP"],"lobbyists":["JONATHON JONES","SEAN RICHARDSON","ASHLI PALMER","COREY MALMGREN","LINDSEY LEDWIN","JOHN GONZALEZ","EMILY KIRLIN"],"issues":["HCR","MMM","DEF"],"sampleDescriptions":["Issues surrounding treatment of rare diseases. Issues related to price and transparency.","Issues related to price and transparency. Issues related to Part D drug benefit.","HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - Issues related to drug pricing.","HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - Issues related to drug pricing. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act","Issues related to drug pricing. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act","Issues related to drug pricing. H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act","Issues related to drug pricing; Issues related to Sickle Cell disease.","Issues related to drug pricing; Issues related to face to face meetings improve oversight of agency commitments.","Issues related to drug pricing; Issues related to face-to-face meetings improve oversight of agency commitments: issues relating to cancer research.","Issues related to drug pricing; Issues related to H.R.7142/S.3832 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.","Issues related to Medicaid best price.","Issues related to drug pricing; Issues related to H.R. 7142/S. 3832 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.","Issues related to opioid alternatives.","Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.","Issues related to opioid alternatives; Issues related to H.R. 3838 - SPEED Act; Issues related to S. 2296 - National Defense Authorization Act for Fiscal Year 2026.","Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.","Issues related to opioid alternatives; Issues related to H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; Issues related to S. 2296 - National Defense Authorization Act for Fiscal Year 2026.","Issues related to opioid alternatives; Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60)."],"years":[2018,2019,2020,2021,2022,2024,2025]}